Reason for request
Inclusion on list of products for hospital use.
Clinical Benefit
| Substantial |
The actual benefit of ACTILYSE 2 mg is substantial. |
Clinical Added Value
| minor |
ACTILYSE 2 mg provides a minor improvement in actual benefit (IAB IV) in terms of efficacy in comparison with ACTOSOLV UROKINASE. |
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
NBDKF5M9cVwJ40Au
